KRAS and leukemia: These changes in early glycolytic products, directly linked to GSL biosynthesis, together with reports that the glycolysis inhibitor 2DG significantly reduces cellular HexCer levels in leukemia cells23, strongly support our contention that KRAS diverts glucose flux into GSL pathways.